TY - JOUR
T1 - How high can we go with phenytoin?
AU - Kozer, Eran
AU - Parvez, Shahid
AU - Minassian, Berge A.
AU - Kobayashi, Jeff
AU - Verjee, Zul
AU - Koren, Gideon
PY - 2002
Y1 - 2002
N2 - Phenytoin is an effective anticonvulsant, but high serum phenytoin concentrations may be associated with serious toxicity. The upper limit for the therapeutic serum concentration of phenytoin is considered to be 80 μmol/L. However, in some situations higher serum concentrations are needed to control seizures. The authors describe a 9-year-old girl who needed concentrations twice the normal amount to control recurrent episodes of decreased levels of consciousness. Except for nystagmus, she had no other signs of phenytoin toxicity. This patient highlights the critical principle in therapeutic drug monitoring of individualizing drug therapy. Although some patients receiving phenytoin may achieve seizure control with "subtherapeutic" levels (i.e., <40 μmol/L), others may need supratherapeutic levels, as was the case with this patient. Clinicians should be careful not to treat "numbers" (i.e., serum concentrations), but rather the patient's clinical condition, with a careful balance between therapeutic advantage and adverse effects.
AB - Phenytoin is an effective anticonvulsant, but high serum phenytoin concentrations may be associated with serious toxicity. The upper limit for the therapeutic serum concentration of phenytoin is considered to be 80 μmol/L. However, in some situations higher serum concentrations are needed to control seizures. The authors describe a 9-year-old girl who needed concentrations twice the normal amount to control recurrent episodes of decreased levels of consciousness. Except for nystagmus, she had no other signs of phenytoin toxicity. This patient highlights the critical principle in therapeutic drug monitoring of individualizing drug therapy. Although some patients receiving phenytoin may achieve seizure control with "subtherapeutic" levels (i.e., <40 μmol/L), others may need supratherapeutic levels, as was the case with this patient. Clinicians should be careful not to treat "numbers" (i.e., serum concentrations), but rather the patient's clinical condition, with a careful balance between therapeutic advantage and adverse effects.
KW - Child
KW - Drug monitoring
KW - Phenytoin
UR - http://www.scopus.com/inward/record.url?scp=0036001237&partnerID=8YFLogxK
U2 - 10.1097/00007691-200206000-00010
DO - 10.1097/00007691-200206000-00010
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 12021630
AN - SCOPUS:0036001237
SN - 0163-4356
VL - 24
SP - 386
EP - 389
JO - Therapeutic Drug Monitoring
JF - Therapeutic Drug Monitoring
IS - 3
ER -